External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2

Abstract

Atazanavir increases plasma bilirubin levels in a concentration-dependent manner. Due to less costly and readily available assays, bilirubin has been proposed as a marker of atazanavir exposure. In this work, a previously developed nomogram for detection of suboptimal atazanavir exposure is validated against external patient populations. The bilirubin nomogram was validated against 311 matching bilirubin and atazanavir samples from 166 HIV-1-infected Norwegian, French, and Italian patients on a ritonavir-boosted regimen. In addition, the nomogram was evaluated in 56 Italian patients on an unboosted regimen. The predictive properties of the nomogram were validated against observed atazanavir plasma concentrations. The use of the nomogram to detect non-adherence was also investigated by simulation. The bilirubin nomogram predicted suboptimal exposure in the patient populations on a ritonavir-boosted regimen with a negative predictive value of 97% (95% CI 95–100). The bilirubin nomogram and monitoring of atazanavir concentrations had similar predictive properties for detecting non-adherence based on simulations. Although both methods performed adequately during a period of non-adherence, they had lower predictive power to detect past non-adherence episodes. Using the bilirubin nomogram for detection of suboptimal atazanavir exposure in patients on a ritonavir-boosted regimen is a rapid and cost-effective alternative to routine measurements of the actual atazanavir exposure in plasma. Its application may be useful in clinical settings if atazanavir concentrations are not available.

Authors and Affiliations

Dinko Rekić, Daniel Röshammar, Martin Bergstrand, Joel Tarning, Andrea Calcagno, Antonio D’Avolio, Vidar Ormaasen, Marie Vigan, Aurélie Barrail-Tran, Michael Ashton, Magnus Gisslén, Angela Äbelö

Keywords

Related Articles

CNS drug delivery: Opioid peptides and the blood-brain barrier

Peptides are key regulators in cellular and intercellular physiological responses and possess enormous promise for the treatment of pathological conditions. Opioid peptide activity within the central nervous system (CNS)...

Hidalgo, I. J., Raub, T. J., and Borchardt, R. T.: Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability, Gastroenterology, 96, 736–749, 1989—The Backstory

This manuscript was written with the knowledge and input of Ismael J. Hidalgo and Thomas J. Raub, who were coauthors of the 1989 Gastroenterology paper describing for the first time Caco-2 cell monolayers as a cell cultu...

Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn

The online version of this article (doi:10.1208/s12248-012-9395-9) contains supplementary material, which is available to authorized users.

Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches

The online version of this article (doi:10.1208/s12248-015-9745-5) contains supplementary material, which is available to authorized users.

Download PDF file
  • EP ID EP681088
  • DOI  10.1208/s12248-012-9440-8
  • Views 61
  • Downloads 0

How To Cite

Dinko Rekić, Daniel Röshammar, Martin Bergstrand, Joel Tarning, Andrea Calcagno, Antonio D’Avolio, Vidar Ormaasen, Marie Vigan, Aurélie Barrail-Tran, Michael Ashton, Magnus Gisslén, Angela Äbelö (2013). External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. The AAPS Journal, 15(2), -. https://europub.co.uk/articles/-A-681088